Teknisk analyse af Abiomed den 15-01-2020 kurs 75$

By 16. januar 2020 februar 23rd, 2020 En kommentar

Abiomed er en global leder inden for sundheds-teknologi og innovation. Abiomed producerede det første mekanisk hjerte og kom fornyeligt med verden mindste hjertepumpe til patienter med hjerte problemer.

Her er de vigtige tal fra Q3-19 den 13-1-2020.

SAN FRANCISCO--(BUSINESS WIRE)--Jan. 13, 2020-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported preliminary, unaudited, third quarter fiscal 2020

  • Revenue of approximately $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019.

Abiomed had a strong start to the quarter across all geographies

  • Highlighted by 24% global revenue growth and 16% growth in U.S. patient usage in October.
  • Preliminary unaudited total U.S. revenue grew 8% to $185.6 million from $172.6 million in the prior fiscal year. U.S. patient usage grew 5% in comparison with the same period of fiscal 2019.
  • Outside the U.S., total revenue for the quarter totaled $36.0 million, an increase of 29% compared to revenue of $28.0 million during the same period of fiscal 2019, due to strength in Germany and Japan.

Her kan man se udviklingen i omsætning og indtjening hos Abiomed fra 2005-2020

Billede 2 viser virksomhedens finansielle værdier og antal patenter på deres produkter.

Her er der oversigt over de forskellige størrelser på deres nyeste produkt IMPELLA hjertepumpe, som er den mindste og nyeste generation af hjertepumpe, som skal være med til at øge deres omsætning og indtjening i de næste mange år.

Oversigt over effektiviteten af Impella hjertepumpe.

Teknisk analyse af Abiomed på uge chart fra den 15-1-20 viser, at aktien steg fra kurs omkring 100$ juni-2016 til kurs 419$ i okt-2018. Sælgerne kom på bane og pressede kursen ned, idet de ikke var tilfreds med virksomhedens indtjening. I løbet et år, faldt kursen fra 419$ til kurs omkring til 150$, hvor køberne så kursen som interessant og kom på banen og indtil videre har holdt hånd under kursen. Kurs 173$ er 0.786% fibonacci retracement, som er den sidste støtte til kursen, når vi snakker om korrektion. Som det kan ses på analysen, er der blevet dannet doblet bund, hvor køberne kommer på banen og køber op. Kursen på uge chart er ved at bryde op gennem 20SMA, som er den første tegn på, at stigningen er på vej og 20SMA bliver støtte til kursen, når kursen bryder op.

Teknisk analyse af Abiomed på 4H chart (fra august-19 til jan-2020) viser, at der er blevet dannet ABCD formation med første target kurs 225$ og anden target kurs 269$. Der er kortsigtet modstand ved kurs 200$ og ved lukke kurs over 200$, vil der med store sandsynlighed komme flere køber på banen og presse kursen op til mit target. Man kan også se doblet bund, som er støtte til kursen. Der er også blevet dannet bullish hammer candelstick mønstre på 4H chart, som fortæller mig, at køberne er aktive. Sælgerne kom på bane med meget højt volumen, men kunne ikke presse kursen under støtte zone, hvilket er et meget positive tegn på kursudviklingen i fremtiden.

Teknisk analyse af Abiomed på 30min chart (fra 16-dec-19 til 15-1-2020) viser, at på kort sigt er kursen kommet over 20SMA, MACD og RSI er stigende og køberne er kommet på banen med høj volumen, som indikerer, at en eventuel stigning er på vej.

Disclaimer :

Jeg har selv købt en position i virksomheden i kurs omkring 173$ og er lang i aktien, så længe kursen er over 150$.

Strategien:

At købe aktien til både swing trade eller langtidsinvestering i kurs omkring kurs 175$ med stoploss i kurs 150-155$ med target i kurs 225$ og videre op til 269$. Man kan købe en position nu og supplerer med flere ved lukke kurs over 200$.

Husk, fysisk eller metalt stoploss, idet der er ikke nogen, der ved, om aktien er i kurs 250$ om nogle uger/måneder, eller om sælgerne kan presse kursen under 150$.

En kommentar

  • admin siger:

    Her er Q3 rengskabet fra Abiomed den 6-2-2020.
    Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin
    February 6, 2020
    DANVERS, Mass.–(BUSINESS WIRE)–Feb. 6, 2020– Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70.3 million, up 13%, compared to $62.4 million in the same period of fiscal 2019.
    Financial and operating highlights for the third quarter fiscal 2020 include:
    U.S. revenue totaled $185.6 million, an increase of 8% compared to revenue of $172.6 million during the same period of fiscal 2019 with U.S. patient usage of Impella heart pumps up 5%.
    Abiomed had a strong start to the quarter across all geographies, highlighted by 24% global revenue growth and 16% growth in U.S. patient usage in October. The company was negatively impacted at a conference by two misleading presentations from observational databases representing less than 4% of our patients over the time period and excluded patients requiring escalation on IABP and all ECMO patients. These conclusions conflict with scientific protocols for observational databases and Impella outcomes reported in more robust, previously published, FDA-audited, peer-reviewed, real-world studies and randomized controlled trials. The totality of the Impella clinical data with 7 FDA studies, 5 post-approval studies and numerous physician-initiated studies demonstrates Impella is safe and effective for high-risk PCI, cardiogenic shock, and right heart failure. The response is detailed in our press release and video publication review.
    Outside the U.S., revenue totaled $36.0 million, an increase of 29% compared to revenue of $28.0 million during the same period of fiscal 2019. Specifically, Japan revenue was $8.7 million in the quarter, up 61% compared to the same period of fiscal 2019.
    Gross margin was 82.0% compared to 83.0% during the same period of fiscal 2019.
    Operating income was $70.3 million, or 31.7% operating margin compared to $62.4 million, or 31.1% operating margin in the same period of fiscal 2019.
    GAAP net income was $69.2 million, or $1.51 per diluted share, which includes a $17.8 million, or $0.39 per share, unrealized gain from our investment in Shockwave. This compares to GAAP net income of $44.9 million or $0.97 per diluted share for the prior fiscal year.
    The company generated operating cash flow of $89.4 million in the third quarter and $228.3 million year to date, an increase of 26.0% versus prior year. As of December 31, 2019, the company had $595.5 million of cash and marketable securities and maintains no debt.
    On October 31, the company announced the first U.S. patients treated with Impella 5.5 with SmartAssist. Designed for heart surgeons, Impella 5.5 with SmartAssist is the first and only forward flow heart pump designed for axillary implant with a smaller profile, weaning algorithms and gives patients the ability to ambulate which has been shown to improve outcomes. The Impella 5.5 with SmartAssist is being introduced in the U.S. through a controlled rollout at hospitals with established heart recovery protocols.
    On November 14, the company announced a comprehensive publication review of cost and comparative effectiveness of Impella in high-risk PCI and cardiogenic shock. The data, from a robust body of US and European evidence from 2004 – 2019, includes the PROTECT II FDA randomized controlled trial, data from the Centers for Medicare & Medicaid Services MedPAR database and more than 20 peer-reviewed clinical publications on cost-effectiveness. It demonstrates that Impella use in high-risk PCI (Protected PCI) and cardiogenic shock, when compared to intra-aortic balloon pump (IABP) or other therapies, is associated with improved patient outcomes and reduced costs.
    On December 16, the company announced the initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle for 30 minutes with an Impella heart pump prior to opening blocked arteries will reduce infarct size after a heart attack and lead to a reduction in future heart failure rates. Abiomed announces today 12 patients have been enrolled and 10 of the 60 hospitals have IRB approval. If the STEMI DTU trial is successful, it could annually benefit 200,000 heart attack patients in the United States and more than 4 million patients outside the United States.
    On January 13, the company presented at the 38th Annual J.P. Morgan Healthcare Conference. A webcast of the presentation with automatic slide advance and animations is available on the investor section of our website.
    “Abiomed remains steadfast on our goal of creating the new field of heart recovery and becoming the standard of care for circulatory support for high-risk PCI and cardiogenic shock,” said Abiomed Chairman, President and CEO, Michael R. Minogue. “Today, we are announcing the start of the next wave of clinical studies designed by the true experts in the field with best practice protocols derived from 15 years of clinical experience and studies. In the history of the company, I feel most confident now about the strength of our innovation, clinical outcomes with protocols, and field team. We will remember this time and recognize the opportunity to propel us forward on our path for CLASS I guidelines for percutaneous unloading heart pumps called Impella.”
    FISCAL YEAR 2020 OUTLOOK
    As previously announced in January, the company revised its 2020 revenue guidance to be in the range of $846 million to $877 million, an increase of 10% to 14%, respectively. The company maintains its fiscal year 2020 guidance for GAAP operating margin within the range of 28% to 30%.

Kommentarer